Genelux CORP 10-K annual reports

Genelux Corporation reported increased net losses for 2025 but extended its cash runway into the first quarter of 2027 following recent capital raises, while advancing its oncolytic viral immunotherapy pipeline.

Genelux Corporation files an amendment to its annual report on Form 10-K to include Part III information regarding directors, executive officers, and corporate governance.

Genelux Corporation's 10-K filing highlights its focus on developing oncolytic viral immunotherapies, particularly Olvi-Vec, for aggressive solid tumors, and outlines its clinical development strategy, manufacturing capabilities, and financial position.

Genelux Corporation's 2023 annual report details the company's financial status, clinical trial progress, and strategic initiatives in developing oncolytic viral immunotherapies.